With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage
February 22nd 2018CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry
February 21st 2018Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.
The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"
February 21st 2018Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.